Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12166
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMacIsaac, Richard Jen
dc.contributor.authorEkinci, Elif Ien
dc.contributor.authorJerums, Georgeen
dc.date.accessioned2015-05-16T01:49:04Z-
dc.date.available2015-05-16T01:49:04Z-
dc.date.issued2014-04-09en
dc.identifier.citationKidney International 2014; 86(1): 50-57en
dc.identifier.govdoc24717301en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12166en
dc.description.abstractThe concept of microalbuminuria has been central to the development of clinical practice and research in the area of diabetic kidney disease (DKD). However, in recent times, the value of a paradigm of DKD based solely on microalbuminuria has been questioned. Although both the absolute level and rate of change of microalbuminuria are linked to the development and progression of DKD, microalbuminuria on its own lacks the necessary sensitivity or specificity to accurately predict kidney outcomes for people with diabetes. The development of microalbumiuria can no longer be viewed as a committed and irreversible stage of DKD, as spontaneous remission is now reported as a common occurrence. In addition, the absence of microalbuminuria or its progression to proteinuria does not signify that an individual patient is safe from a progressive decline in glomerular filtration rate (GFR). Furthermore, although reductions in albuminuria within the microalbuminuric range can be linked to a slower GFR decline in observational studies, this relationship has not been robustly demonstrated in intervention studies. Conclusions regarding the kidney health of individuals with diabetes will continue to be flawed if an inappropriate emphasis is placed on the presence or absence of albuminuria or changes in albuminuria within the microalbuminuric range. This has important implications in terms of undermining the value of microalbuminuria as a surrogate renal end point for intervention trials. There is a need to develop broader models of progressive DKD that include novel pathways and risk markers apart from those related to the traditional 'albuminuric pathway' to renal impairment.en
dc.language.isoenen
dc.title'Progressive diabetic nephropathy. How useful is microalbuminuria?: contra'.en
dc.typeJournal Articleen
dc.identifier.journaltitleKidney Internationalen
dc.identifier.affiliationDepartment of Endocrinology and Diabetes, St Vincent's Hospital, Melbourne and Professorial Fellow, University of Melbourne, Fitzroy, Victoria, Australiaen
dc.identifier.affiliationUniversity of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationEndocrine Centre, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationMenzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia-
dc.identifier.affiliationDepartment of Medicine, Austin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1038/ki.2014.98en
dc.description.pages50-7en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/24717301en
dc.identifier.orcid0000-0003-2372-395X-
dc.type.austinJournal Articleen
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptEndocrinology-
crisitem.author.deptEndocrinology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Feb 5, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.